RE:RE:J and J Tar 200 claiming a high CR % for NMIBCCompared to the original post above, there is more recent data
TAR-200 monotherapy provides complete response rate of 84% in patients with BCG-unresponsive high-risk NMIBC, based on published data, without the need for re-induction
By 12 months the estimated CR is down to 57.4% which is still good but keep in mind that this after a first year in which they are being treated every 3 weeks until 8 months are completed. After that they go to an every 3 month treatment. So I'm assuming that the FDA is going want to know what the 450 day and longer data is like as if it tails off further.
Remember adstiladrin fell off bigtime between 12 and 24 months.